Alliances
Under the agreement, Merck can use Synthekine’s surrogate cytokine agonist platform to discover, develop, and sell new cytokine-based treatments for up to two cytokine targets.
Yet another busy week for clinical trial news. Here’s a look.
Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.
The osteoarthritis drug tanezumab gets permanent leave from the market. The decision of stopping production was due to negative feedback from the regulators.
A large number of people were waiting for the breast cancer vaccine. Now, at present, the world has witnessed the first potential vaccine. Let’s take a look at it.
Teva Pharmaceuticals inked a deal with MODAG GmbH to license and develop two of MODAG’s compounds in neurodegenerative disease, anle138b and sery433.
Mammoth Biosciences just announced a collaboration with Vertex to develop in vivo gene-editing therapeutics for patients with either of two serious, but not-yet-disclosed diseases.
Merck entered into collaborations with three different companies as it continues to assess Keytruda in combination with experimental drugs in different cancer indications.
C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.
Saama Technologies secured a $430 million investment from the Carlyle Group and venture funds from some of the pharmaceutical industry’s biggest companies.
PRESS RELEASES